Sumitomo Pharma Canada

Sumitomo Pharma Canada is a leading pharmaceutical company based in Mississauga, Ontario, serving as the Canadian subsidiary of the global Sumitomo Pharma organization. The company specializes in the commercialization of innovative therapies across several key therapeutic areas, including psychiatry, neurology, urology, and oncology. Formerly known as Sunovion Pharmaceuticals Canada, the entity rebranded in 2023 to align with its global parent organization's identity and expanded portfolio. Its current commercial portfolio features significant treatments such as Latuda for schizophrenia and bipolar depression, and Gemtesa for overactive bladder. Sumitomo Pharma Canada is committed to addressing unmet medical needs through a robust commercial infrastructure and strategic partnerships within the Canadian healthcare landscape.